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Azacitidine might be beneficial in a subgroup of
older AML patients compared to intensive
chemotherapy: a single centre retrospective study
of 227 consecutive patients
Lieke H van der Helm1†, Ellen RM Scheepers1†, Nic JGM Veeger1, Simon MGJ Daenen1, André B Mulder2,
Eva van den Berg3, Edo Vellenga1* and Gerwin Huls1
Abstract
Background: Treatment options in older acute myeloid leukaemia (AML) patients include intensive chemotherapy,
best supportive care (BSC), and hypomethylating agents. Currently, limited data is available on hypomethylating
agents in older AML patients in unselected patient populations.
Methods: To compare the effectiveness of azacitidine with conventional therapy, we collected data of 227
consecutive AML patients (≥60 years) who were treated with azacitidine (N = 26), intensive chemotherapy (N = 90),
or BSC (N = 97).
Results: Azacitidine-treated patients were older and had more comorbidities, but lower white blood cell- and bone
marrow blast counts compared with intensive chemotherapy patients. Complete or partial response was achieved in
42% of azacitidine-treated patients and in 73% of intensive chemotherapy patients (P = 0.005). However, the overall
survival (OS) was similar (1-year-OS 57% versus 56%, P = 0.93; 2-year-OS 35% versus 35%, P = 0.92), and remained
similar after correction for risk factors in a multivariate analysis. Patients treated with BSC had an inferior OS (1-year-
and 2-year-OS 16% and 2%, P < 0.001). Compared to intensive chemotherapy, azacitidine-treated patients spent less
days in the hospital (median in first three months 0.5 versus 56, P < 0.001), and needed less red blood cell and
platelet transfusions (median per month 2.7 versus 7, P < 0.001 and 0.3 versus 5, P < 0.001) in the first three months.
Conclusions: Azacitidine treatment is associated with a comparable OS but higher tolerability in a subgroup of older
AML patients compared with intensive chemotherapy. Patients receiving BSC had a poor prognosis.
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Background
Acute myeloid leukaemia (AML) is characterised by a dif-
ferentiation defect of haematopoietic stem- and progenitor
cells, leading to the accumulation of blast cells and
cytopenias. The incidence of AML increases with age, with
a median age at diagnosis of approximately 70 years [1].
Older AML patients generally have a poor prognosis com-
pared to younger patients due to a higher incidence of
comorbidities, higher rates of treatment related mortality,
and adverse disease characteristics, associated with resist-
ant disease and relapses [2-5]. Median overall survival (OS)
of patients over 60 years of age treated with intensive
chemotherapy is less than 1 year, with complete remission
(CR) rates of about 50% and a treatment related mortality
of at least 15%, indicating an unfavourable risk-benefit ratio
of intensive chemotherapy [6,7].
Nevertheless, several studies suggest that older AML
patients benefit from treatment. A small randomized
clinical trial by the HOVON study group and an ana-
lysis of the Swedish Acute Leukemia Registry showed
that standard intensive treatment improves early death
* Correspondence: e.vellenga@umcg.nl
†Equal contributors
1Department of Haematology, University Medical Centre Groningen,
University of Groningen, Hanzeplein 1, Groningen 9713 GZ, The Netherlands
Full list of author information is available at the end of the article
JOURNAL OF HEMATOLOGY
& ONCOLOGY
© 2013 van der Helm et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
van der Helm et al. Journal of Hematology & Oncology 2013, 6:29
http://www.jhoonline.org/content/6/1/29
rates and long-term survival compared to best supportive
care only (BSC) in older patients [8-10]. In an additional
prospective randomized trial it was demonstrated that low-
dose cytarabine treatment was superior to BSC and hy-
droxyurea in patients with favourable- or intermediate-risk
cytogenetics [11].
The optimal treatment of older AML patients in daily
clinical practice remains challenging. A choice should be
made between intensive chemotherapy, less intensive
treatment, and palliation, considering individual risks
and benefits [7,12]. To guide physicians in their decisions,
several prognostic factors have been identified and risk
scores have been developed based on age, performance sta-
tus, comorbidities, cytogenetics, molecular markers, clin-
ical variables, and laboratory measurements [13-17].
Recently, the DNA methyltransferase inhibitor azacitidine
has become available for MDS and AML patients with up
to 30% bone marrow blast. A superior OS has been demon-
strated in AML patients with 20–30% bone marrow blasts
treated with azacitidine compared to conventional treat-
ment [18,19]. Two recent studies showed a beneficial out-
come in previously untreated AML patients, including
patients with more than 30% bone marrow blasts, who
were treated with azacitidine [20,21]. However, limited data
is available on the treatment of older unselected AML pa-
tients with azacitidine compared to conventional treatment
options. To study the impact of azacitidine and conven-
tional care options in routine clinical practice, we analysed
the treatment results of 227 consecutive newly diagnosed
AML patients of 60 years and older in our centre.
Results
Baseline characteristics of the study population
The study population included 227 consecutive newly di-
agnosed AML patients of 60 years and older. Patients were
treated according to one of the following main strategies:
26 (11%) patients were treated with azacitidine, 90 (40%)
patients were treated with intensive chemotherapy, 97
(43%) patients were treated with best supportive care
(BSC), and 14 (6%) patients were diagnosed with acute
promyelocytic leukaemia (APL) and treated with all-trans
retinoic acid (ATRA)-containing intensive chemotherapy
(Additional file 1: Figure S1). These fourteen APL patients
were excluded from comparisons of azacitidine with inten-
sive chemotherapy, because of the alternative treatment
strategy and superior OS. Patients who were treated with
azacitidine completed a median of 6 (1–30) cycles. All
azacitidine patients started with the standard dose (7 days
75 mg/m2/day), except for one patient with pancytopenia
and malaise at diagnosis who received 50 mg/m2/day. A
dose reduction of 30% was made in one patient after 10 cy-
cles and a schedule change from 7 to 5 days was applied in
one patient after 13 cycles. Failure to receive at least three
cycles of azacitidine was reported in six (23%) patients; the
reason of interruption was early death (N= 4), or pancyto-
penia (N= 2).
Baseline patient- and disease characteristics of the dif-
ferent treatment groups are shown in Table 1. Consider-
ing patient related factors: patients who were treated
with azacitidine and BSC were significantly older than
patients treated with intensive chemotherapy (P < 0.001).
Patients receiving azacitidine had a superior perform-
ance (P = 0.002), and patients receiving BSC had a worse
performance (P = 0.003) compared to patients receiving
intensive chemotherapy. The HCT-comorbidity score
was worse in patients treated with azacitidine (P = 0.029)
and BSC (P < 0.001) compared to intensive chemother-
apy. Considering disease related factors: the percentage
of secondary AML (including therapy related AML,
prior MDS, and prior myeloproliferative neoplasms) was
not significantly different between the treatment groups
(P = 0.089). Patients who were treated with azacitidine
had lower bone marrow (BM) blast counts (P < 0.001),
and white blood cell (WBC) counts (P < 0.001) com-
pared to patients treated with intensive chemotherapy.
Indeed, none of the patients treated with azacitidine had
WBC ≥ 15 × 109/l. The cytogenetic risk score was not
significantly different in patients treated with azacitidine
compared with intensive chemotherapy (P = 0.48), but
cytogenetic risk was worse in patients treated with BSC
compared to intensive chemotherapy (P = 0.005). In 23
patients, the karyotype was not evaluated at baseline.
Allogeneic hematopoietic stem cell transplantation
(allo-SCT) was applied in 14 patients following induction
chemotherapy and also in one patient after azacitidine
treatment. Baseline characteristics of these allo-SCT pa-
tients are shown in Additional file 2: Table S1. All allo-
SCT patients received reduced intensity conditioning
with fludarabine (30 mg/m2 for 3 subsequent days) and 2
Gray total body irradiation (TBI) before transplantation.
All patients received mobilised peripheral blood stem
cells, that were obtained from HLA matched siblings in
11 patients and from matched unrelated donors in 4
patients. Since transplant strategies have evolved during
the study period, the last years, patients under the age
of 70 in CR after two cycles of chemotherapy with a
10/10 matched donor available received an allogeneic
hematopoietic cell transplantation. Indeed, of the pa-
tients younger than 70 years in CR, 12 (24%) received
an allo-SCT, which is 10 (48%) considering this patient
group since 2008.
Response
Response (CR, PR) was achieved in 11 (42%) patients who
were treated with azacitidine, and in 66 (73%) patients who
were treated with intensive chemotherapy, which was sig-
nificantly different (P < 0.001; Table 2). Of the 55 patients
treated with 6-mercaptopurine, two patients met criteria
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for PR. In the azacitidine group, median time to response
from the start of therapy was 4 months (range 3–7 months)
and median duration of response was 16 months. Of the
15 azacitidine-treated patients who did not meet criteria for
response, 5 patients had a stable disease for 5–15 months.
In the intensive chemotherapy group, CR was achieved in
46 (51%) patients after the first induction cycle and, cumu-
latively, in 58 (64%) patients after the second induction
cycle. Median duration of response in the intensive chemo-
therapy group was 11 months.
Table 1 Baseline patient- and disease characteristics by treatment strategy
All patients
(N =213)
Azacitidine
(N =26)
Intensive
chemotherapy
(N =90)
BSC (N =97) P-value
Overall Aza vs IC
Age
Median (range) 68 (60–96) 70 (60–81) 66 (60–74) 71 (60–96) <0.001 <0.001
≥ 70 years 80 (38%) 14 (54%) 10 (11%) 56 (58%) <0.001 <0.001
Sex 0.48 0.27
Male 119 (56%) 17 (65%) 47 (52%) 55 (57%)
Performance score <0.001 0.002
≥ 2 121 (59%) 5 (19%) 47 (54%) 69 (75%)
HCT-comorbidity index <0.001 0.029
Low (0) 98 (46%) 9 (35%) 57 (63%) 32 (33%)
Intermediate (1–2) 66 (31%) 8 (31%) 18 (20%) 40 (41%)
High (> 2) 49 (23%) 9 (35%) 15 (17%) 25 (26%)
AML FAB classification 0.27 0.28
M0/M1 41 (20%) 4 (17%) 21 (21%) 16 (19%)
M2 87 (42%) 8 (33%) 40 (40%) 39 (47%)
M4/M5 51 (25%) 11 (46%) 22 (22%) 18 (22%)
M6/M7 13 (6%) 1 (4%) 4 (4%) 8 (10%)
AML type 0.089 0.056
De novo 139 (65%) 13 (50%) 65 (72%) 61 (63%)
Secondary 74 (35%) 13 (50%) 25 (28%) 36 (37%)
Bone marrow blasts
Median (range) 45 (16–100) 27 (20–88) 52 (20–100) 47 (16–93) <0.001 <0.001
≥ 30% 135 (70%) 11 (42%) 67 (77%) 57 (72%) 0.003 0.001
WBC
Median (range) 5 (0–360) 3 (0–15) 5 (1–236) 7 (1–360) 0.13 <0.001
≥ 15 × 109/l 65 (31%) 0 (0%) 31 (34%) 34 (35%) 0.002 <0.001
LDH
Median (range) 324 (116–4835) 259 (136–1133) 340 (134–2664) 332 (116–4835) 0.15 0.092
> 600 U/l 49 (23%) 2 (8%) 21 (23%) 26 (27%) 0.13 0.15
Cytogenetic risk 0.003 0.48
Favourable 8 (4%) 0 (0%) 4 (4%) 4 (4%)
Intermediate 135 (63%) 18 (69%) 62 (69%) 55 (57%)
Unfavourable 47 (22%) 8 (31%) 21 (23%) 18 (19%)
Not available 23 (11%) 0 (0%) 3 (3%) 20 (21%)
Molecular markers 0.27 0.45
NPMc+/ITD- 13 (7%) 1 (4%) 9 (11%) 3 (4%)
Others 163 (93%) 23 (96%) 75 (89%) 65 (96%)
Patients with promyelocytic leukaemia (N = 14) were excluded from this analysis. Abbreviations: BSC, best supportive care only; Aza vs IC, azacitidine versus
intensive chemotherapy; HCT, hematopoietic cell transplantation; AML, acute myeloid leukaemia; BM, bone marrow; WBC, white blood cell count; LDH, lactate
dehydrogenase; NPMc+/ITD-, cytoplasmic NPM1 without FLT3 internal tandem duplication. Results are reported as N (%) unless otherwise indicated.
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Early mortality and supportive care
The 4- and 8-week mortality rates and the relapse
rates were not significantly different in the azacitidine
group compared with the intensive chemotherapy
group. However, the number of days in the hospital was
significantly lower in patients treated with azacitidine
compared to intensive chemotherapy during the first
three months (0.5 versus 56 days, P < 0.001) and the
following 3 months, i.e. months 4–6 (0 (range 0–8) ver-
sus 0 (range 0–81) days, P = 0.036) after diagnosis
(Table 2; Additional file 3: Figure S2A). Patients treated
with azacitidine needed less red blood cell transfusions
(2.7 versus 7, P < 0.001) and less platelet transfusions
(0.3 versus 5, P < 0.001) during the first three months
after diagnosis compared to patients treated with in-
tensive chemotherapy, but the number of red blood
cell transfusions during months 4–6 was similar in
both treatment groups (0 versus 0.7, P = 0.97) (Table 2;
Additional file 3: Figure S2 B, C). Similar results were
obtained when excluding patients who underwent
allo-SCT (Table 2).
Complications and causes of death
To compare the number of complications and the causes
of death, we selected patients who were treated in the
time period that azacitidine was used (2009–2012).
Grade 3/4 infections occurred in 9 (35%) azacitidine-
treated patients, in 9 (32%) BSC-treated patients, and in
all 46 (98%, 1 missing) patients who received intensive
chemotherapy. Of the patients treated with azacitidine,
17 (65%) had grade 3/4 anaemia or thrombocytopenia at
some time during the treatment. Causes of death in pa-
tients treated with azacitidine, BSC, or intensive chemo-
therapy were disease progression in 8 (62%), 19 (79%),
and 12 (50%) patients, respectively; infection in combin-
ation with progressive disease in 4 (31%), 5 (21%), and 4
(17%) patients, respectively; and infection without dis-
ease progression in 0 (0%) azacitdine and BSC patients,
but in 7 (30%) intensive chemotherapy patients. One pa-
tient treated with intensive chemotherapy died because
of ischemic heart disease. The patient who was treated
with azacitidine and allo-SCT died because of graft-
versus-host disease.
Table 2 Treatment outcome of patients treated with azacitidine or intensive chemotherapy
Azacitidine
(N =26)
Intensive chemotherapy (N =90) P-value
All (N =90) Excl. allo-SCT (N = 76) Aza vs all IC Aza vs IC excl. allo-SCT
Overall survival
1-year 57% 56% 50% 0.931 0.801
2-year 35% 35% 31% 0.921 0.501
Response, overall 11 (42%) 68 (76%) 54 (71%) <0.001 0.005
CR 9 (35%) 63 (70%) 49 (65%)
PR 2 (8%) 5 (6%) 5 (7%)
No CR or PR 15 (58%) 22 (24%) 22 (29%)
Early death
within 4 weeks 1 (4%) 4 (4%) 4 (4%) 0.881 0.791
within 8 weeks 2 (8%) 11 (12%) 11 (12%) 0.511 0.401
Relapse/death after response
within 1 year 4 (36%) 39 (57%) 34 (63%) 0.211 0.181
within 2 years 5 (45%) 42 (62%) 37 (69%) 0.301 0.141
Days in hospital, median (range)
month 1–3 0.5 (0–30) 56 (2–85) 54 (2–85) <0.001 0.029
month 4–6 0 (0–8) 0 (0–81) 0 (0–81) 0.036 0.006
RBC transfusions, median per month (range)
month 1–3 2.7 (0–10) 7 (0–32) 7 (0–32) <0.001 <0.001
month 4–6 0 (0–13) 1 (0–8) 0 (0–8) 0.97 0.65
PLT transfusions, median per month (range)
month 1–3 0.3 (0–7) 5 (0–19) 5 (0–19) <0.001 <0.001
month 4–6 0 (0–1) 0 (0–8) 0 (0–8) 0.016 0.047
1Log rank test. Patients with promyelocytic leukaemia (N = 14) were excluded from this analysis. Abbreviations: excl. allo-SCT, excluding patients undergoing
allogeneic hematopoietic stem cell transplantation; IC, intensive chemotherapy; Aza, azacitidine; vs, versus; CI, confidence interval; CR, complete remission;
PR, partial remission; RBC, red blood cell; PLT, platelet. Results are reported as N (%) unless otherwise indicated.
van der Helm et al. Journal of Hematology & Oncology 2013, 6:29 Page 4 of 9
http://www.jhoonline.org/content/6/1/29
Impact of patient- and disease related factors on overall
survival
Median OS of all 227 patients was 7.8 months. Patients
with a good performance score (0–1) at baseline had a
better OS than patients with an adverse score (≥2) (12.6
versus 4.0 months, respectively; P < 0.001) (Additional
file 4: Figure S3A and Additional file 5: Table S2). Cyto-
genetic risk significantly predicted the survival with a
median OS of 5.9 months in patients with favourable-
risk cytogenetics, excluding APL patients, 9.7 months
in patients with intermediate risk cytogenetics, and
3.6 months in patients with unfavourable-risk cytogenetics
(P < 0.001) (Additional file 4: Figure S3B and Additional
file 5: Table S2). Patients with a translocation t(15;17)
(APL) had a superior OS (median not reached) compared
to other AML patients. The median OS of patients with
no karyotype available was 1.9 months, which was similar
to the OS of patients with unfavourable-risk cytogenetics
(P = 0.33) (Additional file 4: Figure S3B and Additional
file 5: Table S2). The nucleophosmin 1 (NPM1) mutation
status and presence of FLT3-internal tandem duplication
(ITD) were determined in 67 of the 80 patients with a
normal karyotype. Nine patients had cytoplasmic NPM1
without FLT3-ITD (NPMc+/ITD-). Although numbers are
small, a trend towards better OS was observed in these
patients compared to patients without NPMc+/ITD-
(median OS 29.5 versus 8.5 months; P = 0.12; Additional
file 4: Figure S3C).
Impact of treatment on overall survival
The OS in the different treatment groups is depicted in
Figure 1. The OS was similar in patients receiving
azacitidine and patients receiving intensive chemotherapy
(Table 2; 1-year OS 57% versus 56%, P = 0.93; 2-year OS
35% versus 35%, P = 0.92). Also when we compared the OS
of patients treated since 2009, when azacitidine became
available, we observed a similar OS in patients receiving
azacitidine and patients receiving intensive chemotherapy
(Additional file 6: Figure S4; 1-year OS 57% versus 51%,
P = 0.80; 2-year OS 35% versus 38%, P = 1.00). Since base-
line differences were present among patients treated with
azacitidine versus intensive chemotherapy, we assessed the
OS in the subgroups of patients aged ≥70 years, patients
with HCTcomorbidity score >0, patients with performance
scores <2, patients with <30% BM blasts, and patients
with <15 × 109/l WBC’s. Also in these subgroups, no
significant differences in OS were observed between
azacitidine and intensive chemotherapy (P = 0.74; P = 0.71;
P = 0.25; P = 0.71; P = 0.95, respectively).
Patients who received BSC had a significantly worse
OS (1-year and 2-year OS 16% and 2%) compared to
azacitidine and intensive chemotherapy (P < 0.001 and
P < 0.001). When we selected for patients with a good
performance score (<2), which was the lesser part of the
BSC group, we still observed a significantly worse OS in
the BSC group compared to azacitidine (P = 0.025) and
intensive chemotherapy (P = 0.004).
The median OS of fifteen patients who underwent allo-
SCT was 22.5 months from the date of diagnosis, while
other patients treated with intensive chemotherapy or
azacitidine had a median OS of 12.9 months (p = 0.05).
After allo-SCT, five patients died due to a relapse (N = 4)
or graft versus host disease (N = 1).
Of the 90 patients treated with intensive chemotherapy,
51 (57%) were included in a clinical trial and 39 (43%) were
treated off-study. Patients treated off-study had more
comorbidities (p < 0.001) than patients included in a trial.
Between these patient groups, no differences in overall
response rates (75% versus 72%; P = 0.81), and no differ-
ences in median OS (14.9 versus 12.9 months, respect-
ively; P = 0.77) were observed (data not shown).
Predictors for overall survival
To assess whether the OS was similar in patients who
were treated with azacitidine and intensive chemotherapy
after correction for patient- and disease related factors,
we performed a multivariate regression analysis. First, we
determined which factors were associated with OS. In
univariate analysis, unfavourable OS was associated with
BSC (versus azacitidine), unfavourable cytogenetic risk or
cytogenetic risk not evaluated (versus intermediate risk),
age ≥70 years, performance score ≥2, and LDH >600 U/l
(Additional file 5: Table S2). Next, we selected from univar-
iate analysis predictors for OS with P < 0.10. Multivariate
analysis confirmed BSC, unfavourable cytogenetic risk, and
LDH >600 U/l as independent adverse predictors for OS.
The survival of patients treated with azacitidine versus in-
tensive chemotherapy was not significantly different after
correction for these factors (P = 0.84).
Figure 1 Overall survival by treatment strategy. The OS is similar
in patients who were treated with azacitidine (N = 26) and intensive
chemotherapy (IC; N = 90), and is worse in patients who received
BSC (N = 97).
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Discussion
In this single centre retrospective study, treatment re-
sults of 227 newly diagnosed consecutive AML patients
aged ≥60 years who have been treated with BSC,
azacitidine, or intensive chemotherapy, were analysed.
This study confirms the dismal prognosis of older AML
patients who receive only BSC, which was either related
to adverse characteristics at baseline or to the treatment
type. To optimise treatment in older patients who are
unfit for chemotherapy, new therapies are developed, in-
cluding azacitidine. A treatment benefit for azacitidine
compared to BSC was observed in a post-hoc analysis of
the AML patients in the AZA-001 randomized trial [19].
In the same trial, also a limited number of patients treated
with intensive chemotherapy was included, but no signifi-
cant differences in OS were observed between patients
treated with azacitidine versus intensive chemotherapy.
In our retrospective study, despite the limitations of the
relatively small number of patients and disparities between
the treatment groups, we observed no significant differ-
ences in OS in patients treated with azacitidine compared
to intensive chemotherapy. Also a time-dependent effect
could be excluded. When corrected for baseline differences
in a multivariate analysis, a HR of 1.07 was found with a
95% CI of 0.58–2.0 when azacitidine and intensive chemo-
therapy were compared. Despite relatively small numbers
resulting in a wide CI, our point estimate (HR = 1.07) does
suggest a comparable treatment effect of azacitidine
treatment versus intensive chemotherapy in older AML
patients with good performance scores and low WBC
counts. Comparable results have been reported recently
by the MD Andersen Cancer Centre in a cohort study
of 671 patients, including 114 patients treated with
hypomethylation-based (either azacitidine or decitabine)
therapy [22]. In this study they also reported a significant
difference in CR rates but similar OS in patients treated
with epigenetic therapy versus intensive chemotherapy.
These observations, in a larger cohort, are in line with our
observations and might suggest that the currently used re-
sponse criteria are not sufficient for evaluating some (less
intensive) treatment strategies. Further, in the perspective
of comparing intensive treatment with less intensive treat-
ment, it is also interesting to note that a small prospective
randomised trial between chemotherapy and low-dose
cytarabine did not result in a survival benefit for intensive
treatment [23].
An important issue, though difficult to analyse, is the
reason why some patients received only BSC, others
azacitidine and others intensive chemotherapy. The pa-
tients receiving azacitidine differed from the intensive
chemotherapy patients in terms of older age, and more
comorbidities, but also better performance, lower WBC
counts, and lower BM blast counts, while the BSC group
consisted of older patients with a high cytogenetic risk
score, a poor performance score, and a high HCT-
comorbidity index. Apparently, although no defined
guidelines were used, the treating physicians seem to
have integrated these baseline characteristics in their
clinical decisions. Azacitidine is currently only registered
for the treatment of AML with bone marrow blasts be-
tween 20% and 30%. However, we have recently analysed
a cohort of 55 AML patients treated in different hospitals
with azacitidine, which included 31% patients with ≥30%
bone marrow blasts. A comparable OS and response
rates were demonstrated in patients with <30% and ≥30%
bone marrow blasts (van der Helm, 2013, in publication).
These findings are in line with the results of the Italian
named patient program and a German trial [20,21]. An
additional advantage of azacitidine is the tolerability
[19,24,25], which is reflected in our study by a lower
number of days in the hospital and a lower number of
red blood cell- and platelet transfusions compared to in-
tensive chemotherapy. In addition, only two of 26
azacitidine-treated patients discontinued treatment be-
cause of drug toxicity.
The ongoing phase III trial of azacitidine versus BSC
versus intensive chemotherapy (AZA-AML-001 trial) is
expected to finally provide the decisive answers for the
optimal treatment schedule for elderly AML patients.
Recently, the results have been reported of a large phase
III trial, comparing the efficacy and safety of decitabine
(20 mg/m2, days 1–5) (N = 242) with treatment choice
(supportive care (N = 28) and low dose cytarabine (N =
215) of older patients with newly diagnosed AML and
poor- or intermediate-risk cytogenetics [26]. The authors
concluded that there was a significant improvement in
median OS with decitabine versus treatment choice.
Conclusions
Azacitidine treatment is associated with a comparable
OS but higher tolerability in a subgroup of older AML
patients compared with intensive chemotherapy. Patients
receiving BSC had a poor prognosis. Therefore, our data
suggest that azacitidine treatment might be a valuable al-
ternative to intensive chemotherapy and should be con-
sidered instead of BSC in older AML patients.
Methods
Patients and data collection
For this retrospective study, data has been collected from
227 consecutive AML patients of 60 years and older who
were diagnosed and treated between January 2002 and
May 2012 at the University Medical Centre Groningen.
Patients were entered in the study after approval by a
scientific review committee and the University Medical
Center Groningen Institutional Review Board. Informed
consent was obtained in accordance with the Declaration
of Helsinki. Data has been collected by studying health
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records of individual patients between October 2011 and
October 2012. The minimal follow-up time was six months.
Diagnoses were made using French-American-British
criteria and World Health Organization (WHO)-2008
criteria [27,28]. Cytogenetic risk was defined according to
the National Comprehensive Cancer Network (NCCN)
guidelines [29]. Baseline comorbidity was quantified by the
haematopoietic cell transplantation (HCT) comorbidity
index, which was previously demonstrated to be a predict-
ive score in AML patients over 60 years of age treated with
intensive chemotherapy [14,30,31].
Treatment
Azacitidine was available in The Netherlands from
December 2008 onwards in a compassionate named pa-
tient program. Azacitidine was administered subcutane-
ously at the approved schedule of 75 mg/m2/day during
7 days every 28 days. It was intended to give at least 6 cycles
of azacitidine and to continue treatment until progression
in patients who responded well. Dose reductions and de-
lays of treatment cycles could be made.
Intensive chemotherapy was administered according
to one of the HOVON studies [9,32,33], which all con-
tain standard dose cytarabine and an anthracycline
(www.hovon.nl). As part of the subsequent HOVON
studies, patients were randomised to receive or not G-CSF,
intermediate dose cytarabine, bevacizumab, clofarabine,
or lenalidomide in addition to the chemotherapy. Of the
patients treated according to HOVON studies, 57% was
officially included in a HOVON study. Allogeneic haemato-
poietic stem cell transplantation could be applied following
induction therapy. Patients with acute promyelocytic leu-
kaemia (APL) were treated with ATRA-containing chemo-
therapy, according to the HOVON 79 study [34].
Best supportive care (BSC) consisted of transfu-
sions, antibiotics, and hospital admissions as needed.
6-Mercaptopurine and hydroxycarbamide could be added
to the treatment. Red blood cell- or platelet transfusions
were given in agreement with general recommendations:
Hb <8 g/dl, or higher in case of comorbidity, and plate-
lets <20 × 109/l or higher in case of bleeding or anti-
coagulant therapy.
Response criteria and study endpoints
Response was evaluated after every treatment cycle of
intensive chemotherapy and azacitidine by blood count
and by bone marrow aspirate if available. Morphologic
CR and partial remission (PR) were defined according to
IWG-2003 criteria for AML [35]. Response duration was
measured from the date at which marrow evaluation
took place in patients achieving CR or PR, until relapse
or death or censoring. OS was measured from the date
of diagnosis. Patients who remained alive were censored
at the time of the last visit to the hospital.
Statistical analysis
Differences between groups in patient characteristics and
response rates were compared using 2-sided Fisher’s exact
tests or chi-square tests for categorical variables and
Kruskal-Wallis tests or Wilcoxon tests for quantitative var-
iables, unless otherwise indicated. Survival curves were es-
timated with the Kaplan-Meier method and differences in
survival were calculated by logrank tests. Predictive factors
for OS were analysed by Wald tests for univariate and
multivariate comparisons. For multivariate analysis, we se-
lected variables with P < 0.10 in univariate analysis. Cox
proportional hazards regression models were used to esti-
mate hazard ratios (HR) and associated 95% confidence in-
tervals (CI). As we aimed to compare azacitidine treatment
with intensive chemotherapy and BSC, the variable “treat-
ment strategy” was pre-added to the multivariate regres-
sion model. A P-value <0.05 was considered significant.
SPSS-20 was used for analysis.
Findings
Response rates were lower in older AML patients treated
with azacitidine compared to intensive chemotherapy,
however, overall survival in these treatment groups was
comparable.
Additional files
Additional file 1: Figure S1. Flow diagram of the study population.
Between January 2002 and May 2012, 227 consecutive AML patients
aged ≥60 years were diagnosed and treated in our hospital.
Abbreviations: AML, acute myeloid leukaemia; APL, acute promyelocytic
leukaemia.
Additional file 2: Table S1. Baseline characteristics of patients who
underwent allogeneic haematopoietic stem cell transplantation.
Additional file 3: Figure S2. Supportive care during treatment with
azacitidine or intensive chemotherapy. (A) The number of days in the
hospital was lower in patients treated with azacitidine compared to
intensive chemotherapy during the first three months (P < 0.001) and the
following 3 months (P = 0.036) after diagnosis. (B) Patients treated with
azacitidine needed less platelet (PLT) transfusions during the first three
months (P < 0.001) and the following three months (P < 0.016) compared
to intensive chemotherapy. (C) Patients treated with azacitidine needed
less red blood cell (RBC) transfusions (P < 0.001) during the first three
months compared to intensive chemotherapy. The median, 5th, 25th, 75th,
and 95th percentile are depicted.
Additional file 4: Figure S3. Impact of patient and disease factors on
overall survival. (A) Patients with WHO performance score 0–1 had a
superior OS compared to patients with performance score ≥2. (B) The
cytogenetic risk score was a strong predictor for OS. Patients with acute
promyelocytic leukaemia (APL) had a favourable survival. The OS of
patients with no cytogenetics available was comparable to patients with
unfavourable-risk cytogenetics. (C) In patients with a normal karyotype, a
trend towards better OS was observed in the presence of cytoplasmic
NPM1 without FLT3-ITD (NPMc+/ITD-) compared to other patients.
Additional file 5: Table S2. Predictors for overall survival: univariate
and multivariate analysis.
Additional file 6: Figure S4. Overall survival by treatment strategy in
the time period that azacitidine was available. The OS was similar in patients
who were treated with azacitidine (N= 26) and intensive chemotherapy
(IC; N= 47), and was worse in patients who received BSC (N = 28).
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